J
John J. Cush
Researcher at University of Texas Southwestern Medical Center
Publications - 41
Citations - 4674
John J. Cush is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 27, co-authored 41 publications receiving 4496 citations. Previous affiliations of John J. Cush include University of Texas at Dallas & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Daniel O. Clegg,Domenic J. Reda,Crystal L. Harris,Marguerite A. Klein,James R. O'Dell,Michele Hooper,John D. Bradley,Clifton O. Bingham,Michael H. Weisman,Christopher G. Jackson,Nancy E Lane,John J. Cush,Larry W. Moreland,H. Ralph Schumacher,Chester V. Oddis,Frederick Wolfe,Jerry A. Molitor,David E. Yocum,Thomas J. Schnitzer,Daniel E. Furst,Allen D. Sawitzke,Helen Shi,Kenneth D. Brandt,Roland W. Moskowitz,H. James Williams +24 more
TL;DR: The GAIT trial as discussed by the authors evaluated the efficacy and safety of glucosamine and chondroitin sulfate as a treatment for knee pain from osteoarthritis in 1583 patients.
Journal ArticleDOI
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
John C. Davis,Désirée van der Heijde,Jürgen Braun,Maxime Dougados,John J. Cush,Daniel O. Clegg,Alan Kivitz,Roy Fleischmann,Robert D. Inman,Wayne Tsuji +9 more
TL;DR: Etanercept is a highly effective and well tolerated treatment in patients with active ankylosing spondylitis and the safety profile of etanercept was similar to that reported in studies of patients with rheumatoid arthritis or psoriatic arthritis.
Journal ArticleDOI
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
Stanley Cohen,Larry W. Moreland,John J. Cush,Maria Greenwald,S Block,William Shergy,P S Hanrahan,M M Kraishi,A Patel,G Sun,Moraye B. Bear +10 more
TL;DR: This study confirms previous observations from a dose-ranging study showing that anakinra, in combination with MTX, is an effective and safe treatment for patients with RA who have inadequate responses to MTX alone.
Journal ArticleDOI
Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis.
John J. Cush,Peter E. Lipsky +1 more
TL;DR: It is demonstrated that lymphocytes isolated from the synovial tissues of RA patients bear an activated phenotype, exemplified by the modulation of CD3 and CD4 and the expression of HLA-DR.
Journal ArticleDOI
Elevated interleukin-10 levels in patients with rheumatoid arthritis.
John J. Cush,Judy B. Splawski,Ranjeny Thomas,Jackie E. Mcfarlin,Hendrik Schulze-Koops,Laurie S. Davis,Kenji Fujita,Peter E. Lipsky +7 more
TL;DR: Data suggest that there is increased production of IL-10 by non-T cells in patients with rheumatoid arthritis, which may contribute to the diminished T cell function and increased antibody and RF production in these patients.